SEC Form 4 filed by Chief Commercial Officer Chiprin Jeff

$IRMD
Medical/Dental Instruments
Health Care
Get the next $IRMD alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chiprin Jeff

(Last) (First) (Middle)
1025 WILLA SPRINGS DRIVE

(Street)
WINTER SPRINGS FL 32708

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 12/11/2024 A 2,990 (2) (2) Common Stock 2,990 $0 2,990 D
Performance-based Restricted Stock Units (3) 12/11/2024 A 2,989 (3) (3) Common Stock 2,989 $0 2,989 D
Explanation of Responses:
1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
2. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
3. The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.
/s/ Jeff Chiprin 12/13/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $IRMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IRMD

DatePrice TargetRatingAnalyst
4/12/2023$50.00Buy
Lake Street
More analyst ratings

$IRMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference

    WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced that it will participate in the 37th Annual Roth Conference.  Iradimed's CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on-one meetings between company management and investors at the 37th Annual Roth Conference, which will be held at the Laguna Cliffs Marriott in Dana Point, CA, on March 17 and 18, 2025. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and

    $IRMD
    Medical/Dental Instruments
    Health Care
  • IRADIMED CORPORATION Announces Fourth Quarter and Full Year of 2024 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.17 Per Share from $0.15 Per Share

    Reports record revenue of $19.4 million for the fourth quarter of 2024, an increase of $1.9 million or 11%, compared to the same period in 2023. Reports GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44 for the fourth quarter of 2024.Reports GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66 for the full year of 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the first quarter of 2025, payable on March 5, 2025. WINTER SPRINGS, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial

    $IRMD
    Medical/Dental Instruments
    Health Care
  • IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025

    WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BI94f1f3be82df46ccb09997e06cb41e49Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-ti

    $IRMD
    Medical/Dental Instruments
    Health Care

$IRMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IRMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$IRMD
SEC Filings

See more

$IRMD
Leadership Updates

Live Leadership Updates

See more
  • IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

    WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

    $IRMD
    Medical/Dental Instruments
    Health Care
  • Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

    Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

    $IRMD
    Medical/Dental Instruments
    Health Care

$IRMD
Financials

Live finance-specific insights

See more
  • IRADIMED CORPORATION Announces Fourth Quarter and Full Year of 2024 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.17 Per Share from $0.15 Per Share

    Reports record revenue of $19.4 million for the fourth quarter of 2024, an increase of $1.9 million or 11%, compared to the same period in 2023. Reports GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44 for the fourth quarter of 2024.Reports GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66 for the full year of 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the first quarter of 2025, payable on March 5, 2025. WINTER SPRINGS, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial

    $IRMD
    Medical/Dental Instruments
    Health Care
  • IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025

    WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BI94f1f3be82df46ccb09997e06cb41e49Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-ti

    $IRMD
    Medical/Dental Instruments
    Health Care
  • IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025

    WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. "We are honored to be included for the second consecutive year on Forbes' List of America's Most Successful Small-Cap Companies," said Roger Susi, President and Chief Executive Officer o

    $IRMD
    Medical/Dental Instruments
    Health Care

$IRMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more